Comparable stake leader
FARALLON CAPITAL MANAGEMENT, L.L.C.
SEC ownership of AGIOS PHARMACEUTICALS, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001439222.
Disclosed value leader
FARALLON CAPITAL MANAGEMENT, L.L.C.
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- AGIO on Nasdaq
- Parsed ownership sources
-
13D/G and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
FARALLON CAPITAL MANAGEMENT, L.L.C.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
FARALLON CAPITAL MANAGEMENT, L.L.C.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001439222
- Issuer location
- Cambridge, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of AGIOS PHARMACEUTICALS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FARALLON CAPITAL MANAGEME...
Disclosed value leader
FARALLON CAPITAL MANAGEME...
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
13F
Lead comparable stake: 9.9%
13D/G row: FARALLON CAPITAL MANAGEMENT, L.L.C.
Showing 1-8 of 50 holder rows.
Quick read
FARALLON CAPITAL MANAGEMENT, L.L.C. leads the comparable SEC ownership view at 9.9%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FARALLON CAPITAL MANAGEMENT, L.L.C.'s linked filing trail.
Comparable ownership
Top 5
FARALLON CAPITAL MANAGEMENT, L.L.C.
9.9%
Farallon Capital Partners, L.P.
8.8%
BlackRock, Inc.
7.8%
STATE STREET CORP
5.3%
VANGUARD CAPITAL MANAGEMENT LLC
5.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT, L.L.C. |
13D/G
13F
Company
|
9.9%
|
$239,950,570
5,917,400 shares
|
$0 | 30 Jun 2026 |
| Farallon Capital Partners, L.P. |
13D/G
Dapice Joshua J.
|
8.8%
|
$146,117,182
5,159,505 shares
|
-$14,583,696 | 31 Dec 2025 |
| BlackRock, Inc. |
13F
13D/G
Company
|
7.8%
from 13D/G
|
$239,582,050
6,455,997 shares
|
— | 30 Jun 2026 |
| STATE STREET CORP |
13F
13D/G
Company · STATE STREET CORPORATION
|
5.3%
from 13D/G
|
$131,144,972
3,533,633 shares
|
— | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
5.3%
|
$104,472,757
3,088,169 shares
|
$0 | 31 Mar 2026 |
| Lynx1 Capital Management LP |
13F
13D/G
Company
|
5.1%
from 13D/G
|
$126,505,652
3,408,937 shares
|
— | 30 Jun 2026 |
| D. E. SHAW & CO, L.P. |
13D/G
|
5.1%
|
$85,832,737
3,034,031 shares
|
$0 | 25 Jun 2026 |
| Paradigm Biocapital Advisors LP |
13D/G
|
4.9%
|
$115,344,498
2,873,555 shares
|
-$6,198,499 | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$5,232,293.
Buys
$0
Insiders: 0
Sells
$5,232,293
Insiders: 8
Net
-$5,232,293
Shares: -166,598
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 166,598
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 34,007 | $0 | $1,064,903 | -$1,064,903 |
| 3-6 | 0 | 80,335 | $0 | $2,521,885 | -$2,521,885 |
| 6-9 | 0 | 33,303 | $0 | $901,977 | -$901,977 |
| 9-12 | 0 | 18,953 | $0 | $743,528 | -$743,528 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 26 reporting-owner rows connected to AGIOS PHARMACEUTICALS, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
26
Largest Forms 3/4/5 holder
Brian Goff
Net 12M change
-$5,232,293
Latest report
04 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Brian Goff | Chief Executive Officer, Director | $11,083,231 | -$1,691,387 | -13% | Mixed | 18 Jun 2026 |
| David P. Schenkein | Director | $10,131,565 | Mixed | 20 Jun 2024 | ||
| Jacqualyn A. Fouse | Director | $5,215,097 | Mixed | 18 Jun 2026 | ||
| Cecilia Jones | Chief Financial Officer | $2,311,755 | -$468,513 | -17% | Mixed | 18 Jun 2026 |
| James William Burns | Chief Legal Officer | $2,114,186 | -$344,390 | -14% | Mixed | 18 Jun 2026 |
| Sarah Gheuens | Chief Medical Officer | $2,068,354 | -$1,625,033 | -44% | Mixed | 04 Aug 2026 |
| Tsveta Milanova | Chief Commercial Officer | $2,028,209 | -$353,311 | -15% | Mixed | 18 Jun 2026 |
| Krishnan Viswanadhan | Chief Strategy and Operations | $1,220,510 | -$184,967 | -13% | Mixed | 18 Jun 2026 |
| David Scadden | Director | $794,315 | -$32,968 | -4% | Mixed | 18 Jun 2026 |
| Maykin Ho | Director | $774,998 | Mixed | 18 Jun 2026 | ||
| John Maraganore | Director | $617,346 | Mixed | 31 Dec 2022 | ||
| Rahul D. Ballal | Director | $613,641 | Mixed | 18 Jun 2026 | ||
| Cynthia Smith | Director | $613,641 | Mixed | 18 Jun 2026 | ||
| I. Foster Cheek | Director | $525,874 | Mixed | 18 Jun 2026 | ||
| Adams Catherine Owen | Director | $471,103 | Mixed | 18 Jun 2026 | ||
| Jeffrey D. Capello | Director | $471,103 | Mixed | 18 Jun 2026 | ||
| Christopher Bowden | Chief Medical Officer | $335,139 | Mixed | 18 Jun 2021 | ||
| Bruce Car | Chief Scientific Officer | $285,085 | Mixed | 01 Mar 2022 | ||
| Jonathan Biller | Chief Financial Officer | $285,085 | Mixed | 01 Mar 2022 | ||
| Theodore James Jr. Washburn | Principal Accounting Officer | $193,578 | -$531,724 | -73% | Mixed | 03 Mar 2026 |
Recent insider transactions for AGIOS PHARMACEUTICALS, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Sarah Gheuens | AGIO | Common stock | Sale | -35.4% | $914,400 | $30.48 | -30,000 | 54,645 | 04 Aug 2026 | Direct |
| Backstrom Jay T. | AGIO | Common stock | Award | 1,447 | 1,447 | 08 Jul 2026 | Direct | |||
| Backstrom Jay T. | AGIO | Restricted stock units | Options Exercise | -33.3% | -1,447 | 2,894 | 08 Jul 2026 | Direct | ||
| Sarah Gheuens | AGIO | Common stock | Sale | -4.52% | $150,503 | $37.56 | -4,007 | 84,645 | 01 Jul 2026 | Direct |
| Sarah Gheuens | AGIO | Common stock | Options Exercise | 10.4% | 8,375 | 88,652 | 01 Jul 2026 | Direct | ||
| Sarah Gheuens | AGIO | Restricted stock units | Options Exercise | -100% | -8,375 | 0 | 01 Jul 2026 | Direct | ||
| Rahul D. Ballal | AGIO | Common stock | Options Exercise | 22.7% | 2,816 | 15,230 | 18 Jun 2026 | Direct | ||
| Rahul D. Ballal | AGIO | Stock options (right to buy) | Award | 14,950 | 14,950 | 18 Jun 2026 | Direct | |||
| Rahul D. Ballal | AGIO | Restricted stock units | Award | 2,927 | 2,927 | 18 Jun 2026 | Direct | |||
| Rahul D. Ballal | AGIO | Restricted stock units | Options Exercise | -100% | -2,816 | 0 | 18 Jun 2026 | Direct | ||
| Jeffrey D. Capello | AGIO | Common stock | Options Exercise | 35% | 2,816 | 10,865 | 18 Jun 2026 | Direct | ||
| Jeffrey D. Capello | AGIO | Stock options (right to buy) | Award | 14,950 | 14,950 | 18 Jun 2026 | Direct | |||
| Jeffrey D. Capello | AGIO | Restricted stock units | Award | 2,927 | 2,927 | 18 Jun 2026 | Direct | |||
| Jeffrey D. Capello | AGIO | Restricted stock units | Options Exercise | -100% | -2,816 | 0 | 18 Jun 2026 | Direct | ||
| I. Foster Cheek | AGIO | Common stock | Options Exercise | 37.7% | 2,816 | 10,284 | 18 Jun 2026 | Direct | ||
| I. Foster Cheek | AGIO | Stock options (right to buy) | Award | 14,950 | 14,950 | 18 Jun 2026 | Direct | |||
| I. Foster Cheek | AGIO | Restricted stock units | Award | 2,927 | 2,927 | 18 Jun 2026 | Direct | |||
| I. Foster Cheek | AGIO | Restricted stock units | Options Exercise | -100% | -2,816 | 0 | 18 Jun 2026 | Direct | ||
| Jacqualyn A. Fouse | AGIO | Common stock | Options Exercise | 1.86% | 2,816 | 154,156 | 18 Jun 2026 | Direct | ||
| Jacqualyn A. Fouse | AGIO | Stock options (right to buy) | Award | 14,950 | 14,950 | 18 Jun 2026 | Direct | |||
| Jacqualyn A. Fouse | AGIO | Restricted stock units | Award | 2,927 | 2,927 | 18 Jun 2026 | Direct | |||
| Jacqualyn A. Fouse | AGIO | Restricted stock units | Options Exercise | -100% | -2,816 | 0 | 18 Jun 2026 | Direct | ||
| Maykin Ho | AGIO | Common stock | Options Exercise | 16.5% | 2,816 | 19,848 | 18 Jun 2026 | Direct | ||
| Maykin Ho | AGIO | Stock options (right to buy) | Award | 14,950 | 14,950 | 18 Jun 2026 | Direct | |||
| Maykin Ho | AGIO | Restricted stock units | Award | 2,927 | 2,927 | 18 Jun 2026 | Direct | |||
| Maykin Ho | AGIO | Restricted stock units | Options Exercise | -100% | -2,816 | 0 | 18 Jun 2026 | Direct | ||
| Adams Catherine Owen | AGIO | Common stock | Options Exercise | 35% | 2,816 | 10,865 | 18 Jun 2026 | Direct | ||
| Adams Catherine Owen | AGIO | Stock options (right to buy) | Award | 14,950 | 14,950 | 18 Jun 2026 | Direct | |||
| Adams Catherine Owen | AGIO | Restricted stock units | Award | 2,927 | 2,927 | 18 Jun 2026 | Direct | |||
| Adams Catherine Owen | AGIO | Restricted stock units | Options Exercise | -100% | -2,816 | 0 | 18 Jun 2026 | Direct | ||
| David Scadden | AGIO | Common stock | Options Exercise | 16% | 2,816 | 20,419 | 18 Jun 2026 | Direct | ||
| David Scadden | AGIO | Stock options (right to buy) | Award | 14,950 | 14,950 | 18 Jun 2026 | Direct | |||
| David Scadden | AGIO | Restricted stock units | Award | 2,927 | 2,927 | 18 Jun 2026 | Direct | |||
| David Scadden | AGIO | Restricted stock units | Options Exercise | -100% | -2,816 | 0 | 18 Jun 2026 | Direct | ||
| Cynthia Smith | AGIO | Common stock | Options Exercise | 22.7% | 2,816 | 15,230 | 18 Jun 2026 | Direct | ||
| Cynthia Smith | AGIO | Stock options (right to buy) | Award | 14,950 | 14,950 | 18 Jun 2026 | Direct | |||
| Cynthia Smith | AGIO | Restricted stock units | Award | 2,927 | 2,927 | 18 Jun 2026 | Direct | |||
| Cynthia Smith | AGIO | Restricted stock units | Options Exercise | -100% | -2,816 | 0 | 18 Jun 2026 | Direct | ||
| Krishnan Viswanadhan | AGIO | Restricted stock units | Award | 3,000 | 3,000 | 18 Jun 2026 | Direct | |||
| Krishnan Viswanadhan | AGIO | Performance share units | Options Exercise | -25% | -3,000 | 9,000 | 18 Jun 2026 | Direct | ||
| Brian Goff | AGIO | Restricted stock units | Award | 39,000 | 39,000 | 18 Jun 2026 | Direct | |||
| Brian Goff | AGIO | Performance share units | Options Exercise | -50% | -39,000 | 39,000 | 18 Jun 2026 | Direct | ||
| James William Burns | AGIO | Restricted stock units | Award | 3,000 | 3,000 | 18 Jun 2026 | Direct | |||
| James William Burns | AGIO | Performance share units | Options Exercise | -25% | -3,000 | 9,000 | 18 Jun 2026 | Direct | ||
| Sarah Gheuens | AGIO | Restricted stock units | Award | 3,000 | 3,000 | 18 Jun 2026 | Direct | |||
| Sarah Gheuens | AGIO | Performance share units | Options Exercise | -25% | -3,000 | 9,000 | 18 Jun 2026 | Direct | ||
| Cecilia Jones | AGIO | Restricted stock units | Award | 3,000 | 3,000 | 18 Jun 2026 | Direct | |||
| Cecilia Jones | AGIO | Performance share units | Options Exercise | -25% | -3,000 | 9,000 | 18 Jun 2026 | Direct | ||
| Tsveta Milanova | AGIO | Restricted stock units | Award | 3,000 | 3,000 | 18 Jun 2026 | Direct | |||
| Tsveta Milanova | AGIO | Performance share units | Options Exercise | -25% | -3,000 | 9,000 | 18 Jun 2026 | Direct |
* marks a reported price that did not pass the local price check.